Reviews/Novel Antibiotics/CAZ-AVI reduces mortality in KPC CRE infections versus older agents
Caz Avi · NOVEL-AB-CAZAVI-01 · v2
Only one study in this corpus actually compares ceftazidime-avibactam against the older drugs it would replace while measuring deaths [12], and that study looked only at organ-transplant patients with a bloodstream infection. In that study fewer patients died on ceftazidime-avibactam than on the older regimens, but the gap was on the edge of what could be chance, and once the authors accounted for how sick the patients were the drug was no longer linked to survival. The clearer, firmer benefit in that study was that patients got better (clinical success), not that fewer died. No other study here tests the same comparison, so there is nothing to confirm the single result against. The panel landed where it did because one borderline result in a narrow group of patients cannot carry a broad claim that the drug saves lives across the whole family of these infections.
A single retrospective cohort [12] is the only paper that directly pits ceftazidime-avibactam against best available therapy on death in carbapenemase-producing K. pneumoniae bloodstream infection; crude 30-day mortality was 13.25% versus 27.3% (P = .053), but 'CAZ-AVI therapy was not independently associated with 30-day mortality' after adjustment. The robust, adjusted benefit in [12] was clinical success (30-day adjusted odds ratio 3.14; 95% CI, 1.17-8.40; P = .023), a different endpoint from mortality. Other papers describe the problem the drug addresses but do not test it: KPC bloodstream and other infections carry high mortality on older agents such as polymyxins [14][16][13], and CRE infection itself adds attributable mortality [8]. Randomised ceftazidime-avibactam trials exist [1][2] but are in non-KPC populations against carbapenem comparators and do not report a mortality benefit in this setting. Several papers instead flag emerging resistance to the drug [9][11] and that monotherapy is often inadequate in vitro [19]. The contested point: The division is whether the lower crude mortality in [12] (13.25% vs 27.3%, P = .053) represents a real drug effect or patient selection. The signal is directionally favourable but sits at borderline significance and disappears on adjustment, where only clinical success remained significant, so the corpus supports a benefit on recovery far more firmly than on survival.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The entire admissible evidence base is a single retrospective cohort [12]; one study cannot establish a reproducible comparative mortality effect, and no corroboration exists in-corpus.
In [12] the mortality signal is the weakest endpoint: crude difference p=0.053 and explicitly 'not independently associated with 30-day mortality' on adjustment. The adjusted, significant benefit is clinical success, a softer endpoint than the claim's 'reduces mortality'.
Where it remains uncertain. The same study [12] states CAZ-AVI was 'not independently associated with 30-day mortality' after adjustment, and no other corpus paper corroborates the comparison.
Aleatory
The crude 30-day mortality gap in [12] (13.25% vs 27.3%) sits at P = .053 in a small subgroup, so random sampling variation cannot be separated from a true effect.
Epistemic
Only [12] is admissible; no second comparative study exists in-corpus to confirm or refute the signal, and resistance reports [9][11] raise durability questions the mortality data cannot address.
Inferential
The adjusted benefit in [12] is clinical success, not mortality ('not independently associated with 30-day mortality'); treating that as a survival effect is an inferential leap.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Provides the only direct CAZ-AVI-vs-older-agents mortality comparison; crude mortality favours CAZ-AVI but only at borderline significance
“In contrast, CAZ-AVI therapy was not independently associated with 30-day mortality.”
Panel auditInternal validity: medium · scope of inference: Solid organ transplant recipients with carbapenemase-producing K. pneumoniae bloodstream infection across 14 centres.Key limitations: retrospective observational · mortality not significant and not independent after adjustment (P=.053) · narrow SOT-recipient population · carbapenemase not confirmed as KPC specifically
1 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One retrospective study with a borderline crude signal that is null after adjustment cannot carry a general comparative mortality claim.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Direct mortality comparison beyond a single cohort. The claim rests on one retrospective study [12] with a borderline, adjustment-fragile signal and no corroboration. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective or randomised comparison of ceftazidime-avibactam versus older best-available therapy in KPC CRE infection with 30-day all-cause mortality as the primary endpoint.
Open question: Does ceftazidime-avibactam reduce all-cause mortality versus older agents in KPC CRE infection outside the transplant bloodstream-infection setting? Why it is still open: The only direct comparison [12] is confined to solid-organ transplant bloodstream infection and its mortality signal is borderline and null on adjustment.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19